An executive at Oruka Therapeutics sold 9,854 shares at $69.72 amid a 700% stock rally over the past year.
Oruka Therapeutics Senior Vice President Arjun Agarwal sold 9,854 shares for approximately $687,000 on June 12 and June 15, 2026. The transaction, disclosed in an SEC filing, was executed at a weighted average price of $69.72 per share.
The sale reduced Agarwal’s direct holdings by 36.83%, from 26,753 to 16,899 shares. The shares were sold following the exercise of 9,459 options, with no indirect or entity-based ownership involved. Oruka’s stock has risen nearly 700% over the past year.
The company, a clinical-stage biotech firm, focuses on monoclonal antibody therapies for inflammatory and immunological conditions, including psoriasis treatments ORKA-001 and ORKA-002.